The latest price target for Pacific Biosciences (NASDAQ:PACB) was reported by Scotiabank on August 28, 2024. The analyst firm set a price target for $7.00 expecting PACB to rise to within 12 months (a possible 278.38% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Pacific Biosciences (NASDAQ:PACB) was provided by Scotiabank, and Pacific Biosciences maintained their sector outperform rating.

The last upgrade for Pacific Biosciences of California Inc happened on November 17, 2023 when UBS raised their price target to $10. UBS previously had a neutral for Pacific Biosciences of California Inc.

The last downgrade for Pacific Biosciences of California Inc happened on April 22, 2024 when JP Morgan changed their price target from N/A to N/A for Pacific Biosciences of California Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacific Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacific Biosciences was filed on August 28, 2024 so you should expect the next rating to be made available sometime around August 28, 2025.

While ratings are subjective and will change, the latest Pacific Biosciences (PACB) rating was a maintained with a price target of $8.00 to $7.00. The current price Pacific Biosciences (PACB) is trading at is $1.85, which is out of the analyst’s predicted range.